This video examines the targeting of IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia.
In this video, Courtney D. DiNardo, MD, of MD Anderson Cancer Center in Houston, discusses targeting IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia (AML).
IDH mutations occur in roughly 20% of AML patients and recent novel therapies have proven to be effective in this setting. A phase I trial on the novel IDH2-inhibitor enasidenib in relapsed/refractory AML was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
DiNardo, who has been involved in many of the AML studies using IDH inhibitors, gave a presentation on this topic during an education session at the meeting.